Vivos Therapeutics, Inc. - VVOS STOCK NEWS

Vivos Therapeutics (NASDAQ: VVOS) has announced the launch of MyoCorrect, a telemedicine service offering orofacial myofunctional therapy (OMT) to enhance the treatment of obstructive sleep apnea (OSA). This initiative aims to provide Vivos-trained providers with greater access to OMT, expected to drive additional revenue through increased Vivos System cases and service fees. Vivos anticipates that MyoCorrect will strengthen its competitive positioning in the OSA market, as trained dentists report numerous benefits from integrating OMT into their treatment protocols.

Vivos Therapeutics reported a 15% revenue increase for full year 2020, reaching $13.1 million, up from $11.4 million in 2019. The fourth quarter revenue hit $3.3 million with a gross profit of $2.7 million, marking an 81% gross margin. Despite a net loss of $12.1 million for the full year, the company surpassed 15,000 cases treated. Financial resilience was aided by a $21.6 million IPO in December 2020. New product launches, including AireO2 and VivoScore, are expected to enhance their market position.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Benzinga Biotech Small Cap Conference on March 25, 2021, at 11:40 am Eastern Time. The conference runs from March 24-25, 2021. Key presenters include CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew. Vivos focuses on innovative treatments for sleep-disordered breathing, particularly mild-to-moderate obstructive sleep apnea (OSA), using non-invasive methods. Interested investors can register for a free spectator pass via the provided link.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced plans to release its financial results for Q4 and the full year ended December 31, 2020, after market close on March 25, 2021. The company will hold a conference call at 5:00 p.m. ET to discuss the results and its growth strategy. Vivos aims to provide innovative treatments for sleep-disordered breathing, specifically mild-to-moderate obstructive sleep apnea (OSA), with its Vivos System oral appliances, proven effective in over 15,000 patients. The company is committed to growth through improved treatment technologies.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Q1 Virtual Investor Summit on March 23, 2021, at 1:30 PM ET. Key executives, including CEO Kirk Huntsman and CFO Brad Amman, will discuss the company's focus on innovative treatments for sleep-disordered breathing, particularly obstructive sleep apnea (OSA). The Vivos System offers a non-invasive, personalized therapy for patients, which has successfully treated over 15,000 patients globally. Interested investors can register for the presentation and access a replay afterward on Vivos' website.

Vivos Therapeutics (NASDAQ: VVOS) announced the opening of its first Pneusomnia clinic in Del Mar, California, aimed at addressing sleep apnea through the Vivos System. This integrated medical-dental center, led by Dr. Mimi Guarneri, will provide innovative, non-invasive treatments for mild-to-moderate obstructive sleep apnea (OSA). The Vivos System is designed to treat the root causes of sleep apnea without requiring lifelong intervention. Additional clinics are planned across the U.S., enhancing patient access to vital screenings and treatments.

Vivos Therapeutics (NASDAQ: VVOS) announced its participation in the 33rd Annual ROTH Conference from March 15-17, 2021. CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew will present on March 16 at 11:30 am ET. Investors can register for the presentation through a provided link and a replay will be available on the company's website. Vivos specializes in innovative treatments for sleep-disordered breathing, particularly mild to moderate obstructive sleep apnea, using its Vivos System that has helped over 18,000 patients globally.

Vivos Therapeutics (NASDAQ: VVOS) has launched VivoScore, a home sleep apnea test utilizing advanced cardiopulmonary technology by SleepImage. This single-sensor device connects to a mobile app, facilitating clinical-grade sleep apnea diagnosis. The pilot study indicated that 56% of tested patients had OSA, with 50% pursuing treatment through the Vivos System. This innovation is expected to lower costs and enhance diagnosis accessibility for untreated sleep apnea patients, addressing a market of roughly 1 billion individuals worldwide. VivoScore is anticipated to significantly boost patient enrollment and revenue for Vivos Therapeutics.

Vivos Therapeutics (NASDAQ: VVOS) announced the formation of a Clinical Advisory Board to enhance the adoption of its innovative treatments for obstructive sleep apnea (OSA), which affects 1 billion people worldwide. The board comprises distinguished experts from sleep medicine and dentistry, bringing decades of experience to ensure the Vivos System remains a leading non-surgical treatment. This move aims to strengthen Vivos' market position and drive further commercial success, leveraging the expertise of its members.